SCHEMBL6862376

SCHEMBL6862376

O=C(O)c1ccc(NC(=O)c2cc(Cl)ccc2NS(=O)(=O)c2ccc(Br)cc2)cc1

nearest known ligand 0.76

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
SLC10A6 Q3KNW5 2/20 0.76
SLC10A2 Q12908 1/20 0.76
SLC10A1 Q14973 1/20 0.76
METAP2 P50579 1/20 0.61
CCR9 P51686 1/20 0.59
GPR27 Q9NS67 7/20 0.57
MEN1 O00255 2/20 0.55
KMT2A Q03164 2/20 0.55
CPT2 P23786 1/20 0.54
CPT1A P50416 1/20 0.54
CPT1B Q92523 1/20 0.54
TP53 P04637 1/20 0.54
AVPR2 P30518 1/20 0.54
ACLY P53396 1/20 0.52
KCNA5 P22460 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6861824 0.94 SLC10A6 (0.87) SLC10A6SLC10A2SLC10A1METAP2GPR27
SCHEMBL6862400 0.93 SLC10A6 (0.71) SLC10A6SLC10A2SLC10A1METAP2GPR27
SCHEMBL5115455 0.92 SLC10A6 (0.88) SLC10A6SLC10A2SLC10A1METAP2CCR9
SCHEMBL6860624 0.90 SLC10A6 (0.64) SLC10A6SLC10A2SLC10A1GPR27MEN1
SCHEMBL1138705 0.90 SLC10A6 (0.63) SLC10A6SLC10A2SLC10A1GPR27MEN1
SCHEMBL6860636 0.89 LMNA (0.64) SLC10A6SLC10A2SLC10A1METAP2CCR9
SCHEMBL6863831 0.89 KMT2A (0.63) SLC10A6SLC10A2SLC10A1GPR27MEN1
SCHEMBL7126120 0.88 SLC10A6 (0.98) SLC10A6SLC10A2SLC10A1METAP2CCR9
SCHEMBL5925293 0.87 SLC10A6 (0.69) SLC10A6SLC10A2SLC10A1METAP2GPR27
SCHEMBL5925251 0.87 SLC10A6 (0.72) SLC10A6SLC10A2SLC10A1METAP2GPR27

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030060460-A1 Such as 4-(2-phenylsulfonylamino-5-chlorobenzoylamino)benzoic acid for use as prostaglandin E2 antagonist or agonist; for inhibition of uterine contraction, analgesics, antidiarrheals, sleep inducers, and/or for increase of vesical capacity OHUCHIDA SHUICHI (JP) 2003-03-27 US claimed
EP-0947500-A1 SULFONAMIDE AND CARBOXAMIDE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 1999-10-06 EP claimed
CN-1213019-C Sulfonamide and carboxamide derivatives and drugs containing same as active ingredient ONO PHARMACEUTICAL CO (JP) 2005-08-03 CN disclosed
US-6790866-B2 SUCH AS 4-(2-PHENYLSULFONYLAMINO-5-CHLOROBENZOYLAMINO)BENZOIC ACID FOR USE AS PROSTAGLANDIN E2 ANTAGONIST OR AGONIST; FOR INHIBITION OF UTERINE CONTRACTION, ANALGESICS, ANTIDIARRHEALS, SLEEP INDUCERS, AND/OR FOR INCREASE OF VESICAL CAPACITY ONO PHARMACEUTICAL CO., LTD. (JP) 2004-09-14 US disclosed
US-20030060460-A1 Such as 4-(2-phenylsulfonylamino-5-chlorobenzoylamino)benzoic acid for use as prostaglandin E2 antagonist or agonist; for inhibition of uterine contraction, analgesics, antidiarrheals, sleep inducers, and/or for increase of vesical capacity OHUCHIDA SHUICHI (JP) 2003-03-27 US disclosed
US-6448290-B1 PROSTAGLANDIN E2 ANTAGONIST OR AGONIST; INHIBITION OF UTERINE CONTRACTION, ANALGESICS, ANTIDIARRHEALS, SLEEP INDUCERS, INCREASING VESICAL CAPACITY, CATHARTIC, SUPPRESSION OF GASTRIC ACID SECRETION, ANTIHYPERTENSIVE, DIURETIC AGENTS ONO PHARMACEUTICAL CO., LTD. (JP) 2002-09-10 US disclosed
CN-1247529-A Sulfonamide and carboxamide derivatives and drugs containing same as active ingredient ONO PHARMACEUTICAL CO (JP) 2000-03-15 CN disclosed
EP-0947500-A1 SULFONAMIDE AND CARBOXAMIDE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 1999-10-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030060460-A1 Such as 4-(2-phenylsulfonylamino-5-chlorobenzoylamino)benzoic acid for use as prostaglandin E2 antagonist or agonist; for inhibition of uterine contraction, analgesics, antidiarrheals, sleep inducers, and/or for increase of vesical capacity CNR1, HCAR1, HCAR2 SLC10A6 1996/4885SLC10A2 617/4885SLC10A1 737/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.